SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors
Status:
Not yet recruiting
Trial end date:
2025-11-22
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of combination of SKB264 and
Pembrolizuamb in patients with selected solid tumors including cervical cancer, urothelial
carcinoma, ovarian cancer, mestastatic castration-resistant prostate cancer.